Q1FY21 results: IRB Infrastructure Developers records net loss of Rs 30.14 crore

Q1FY21 results: IRB Infrastructure Developers records net loss of Rs 30.14 crore

Chinmayee D
/ Categories: Trending, Quarterly Results

IRB Infrastructure Developers Limited, the largest private roads and highways infrastructure developer in India, announced its quarterly results on August 24, 2020.The company posted a consolidated net loss of Rs 30.14 crore for Q1FY21, which declined by 114.59 per cent YoY, as compared to Q1FY20 when it reported consolidated net profit of Rs 206.62 crore.

The consolidated net sales reported in Q1FY21 came in at Rs 1,022.30 crore, which declined by 42.34 per cent YoY from Rs 1,773.04 crore in Q1FY20. At EBITDA level, the company stood at Rs 477.59 crore in Q1FY21 that decreased by 44.17 per cent YoY. For Q1FY20, it posted an EBITDA of Rs 855.41 crore.

EBITDA margin as of Q1FY21 was at 46.72 per cent that declined by 1.53 per cent YoY. The net profit margin in Q1FY21 came in at -2.95 per cent, which declined by 14.60 per cent YoY. The net profit margin in Q1FY20 was at 11.65 per cent.

Company’s toll collections were temporarily affected due persisting lockdowns during the quarter. With gradual relaxation on the lockdown, the normalcy is expected soon as collections for June 2020 surpassed 75 per cent levels on YoY basis.

On Tuesday, despite booking a loss in Q1FY21, the share is trading with gains of 2.21 per cent higher at Rs127.4 in the early trading session on BSE.  

Particulars

Q1FY21

(Rs in cr)

Q1FY20

(Rs in cr)

per cent

change

Net Profit/(Loss)

(30.14)

206.62

-114.59

Net Revenue

1,022.30

1,773.04

-42.34

Operating Profit

477.59

855.41

-44.17

EBITDAM%

46.72

48.25

-1.53

PATM%

-2.95

11.65

-14.60

                                                                                                                                                

                                                                                                                                                               

 

Previous Article Lupin gets USFDA approval for Albuterol Sulfate Inhalation Aerosol
Next Article Pharma companies unlikely to sustain healthy operating performance in Q1: Ind-Ra
Rate this article:
4.5

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR